ArticleJournal of thoracic disease2025
The impact of neuron-related cell adhesion molecule on cellular biological functions and its clinical significance in small-cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuron-related cell adhesion molecule (NrCAM) has been implicated in tumor progression, but its role in small-cell lung cancer (SCLC) remains unclear. This study examined the clinical significance of NrCAM in SCLC and its impact on cellular processes. Methods: Differentially expressed genes (DEGs) in SCLC were identified from The Cancer Genome Atlas (TCGA) datasets (GSE6044, GSE111044, and GSE44447) according to a |log fold change (FC)| >2 and a P value <0.05. Clinical and pathological data, along with tumor tissue samples, were obtained from 43 patients with SCLC treated at Nantong Tumor Hospital from 2017 to 2019. NrCAM expression was analyzed via immunohistochemistry. Results: Immunohistochemical analysis revealed higher NrCAM expression in SCLC tissues as compared to adjacent noncancerous tissues. Patients with high NrCAM expression exhibited shorter survival (P=0.04) and significant associations with tumor-node-metastasis (TNM) stage, tumor size, and differentiation grade (P<0.05). Multivariate Cox analysis identified high NrCAM expression as an independent risk factor for poor prognosis (P=0.04). Conclusions: NrCAM overexpression in SCLC is associated with poor prognosis. Knockdown of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.